Safety Profile and Tumor Response of EGFR-TKIs in Clinical Practice: A Real-World Study in Thailand
Journal of Clinical Medicine · 23.03.2026 · 15 (6) · 2437
DOI: 10.3390/jcm15062437 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 23.03.2026. Verfasst von Pattama Jainan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Rajavithi Hospital, Bangkok 10400, Thailand. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the first-line treatment for patients with non-small cell lung cancer (NSCLC) harboring EGFR mutations. Although EGFR-TKIs can cause various adverse events (AEs), their profiles have not been fully elucidated in Thai patients. This study aimed to determine the incidence, characteristics, severity, and duration of the first AEs and to evaluate their association with tumor response in patients with NSCLC receiving EGFR-TKIs.
Method
This retrospective cohort study was conducted at a super-tertiary care hospital in Thailand. Patients with NSCLC who received EGFR-TKIs between August 2021 and July 2024 were included. Descriptive statistics were used to summarize safety profiles and tumor response. The association between AEs and objective response was assessed using logistic regression.
Results
A total of 187 patients were included in this study. Overall, 177 AEs were observed in patients receiving erlotinib, osimertinib, or gefitinib. The most common cutaneous AEs were rash (30.7%), xerosis (24.1%), and acneiform rash (19.3%), while diarrhea (20.3%) was the most frequent gastrointestinal toxicity. Most AEs were grade 1–2 and occurred within 1 month after treatment initiation. In multivariable logistic regression analysis, pruritus (OR 8.26, 95% CI: 1.00–67.75, p = 0.049) and treatment line (OR 0.27, 95% CI: 0.10–0.68, p = 0.006) were independently associated with objective response.
Conclusion
Most of the AEs occurred early during EGFR-TKI therapy, with cutaneous reactions being the most common and generally mild to moderate. Pruritus and treatment line were independently associated with objective response, suggesting that pruritus may serve as a potential clinical indicator of treatment response and highlighting the importance of monitoring of the EGFR-TKI-related AEs during therapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacy, Rajavithi Hospital, Bangkok 10400, Thailand.
- Department of Pharmacy Practice, College of Pharmacy, Rangsit University, Mueang Pathum Thani 12000, Thailand.
- Faculty of Pharmacy, Pathumthani University, Mueang Pathum Thani 12000, Thailand.
ORCID-Profile: Kamala Sadabpod
Zitieren
APA
Jainan, P., Pongsathabordee, C., Sadabpod, K., Junkrut, T., Jerasirichot, T., Phetchuensakun, O., Paiboonvong, T., & Srithonrat, S. (2026). Safety Profile and Tumor Response of EGFR-TKIs in Clinical Practice: A Real-World Study in Thailand. Journal of Clinical Medicine, 15(6), 2437. https://doi.org/10.3390/jcm15062437
Vancouver
Jainan P, Pongsathabordee C, Sadabpod K, Junkrut T, Jerasirichot T, Phetchuensakun O, et al. Safety Profile and Tumor Response of EGFR-TKIs in Clinical Practice: A Real-World Study in Thailand. Journal of Clinical Medicine. 2026;15(6):2437. doi:10.3390/jcm15062437
BibTeX
@article{Jainan2026,
author = {Jainan, Pattama and Pongsathabordee, Chayanat and Sadabpod, Kamala and Junkrut, Titima and Jerasirichot, Thanakorn and Phetchuensakun, Oran and Paiboonvong, Taniya and Srithonrat, Saranporn},
title = {Safety Profile and Tumor Response of EGFR-TKIs in Clinical Practice: A Real-World Study in Thailand},
journal = {Journal of Clinical Medicine},
year = {2026},
volume = {15},
number = {6},
pages = {2437},
doi = {10.3390/jcm15062437}
}
EUVIMED